Dec 05, 2019 7:00am EST Can-Fite to Attend BioFIT 2019 Conference in Europe with Focus on Partnering Meetings for Namodenoson in NASH
Nov 29, 2019 7:00am EST Can-Fite Reports Third Quarter 2019 Financial Results & Provides Clinical Update
Nov 21, 2019 7:00am EST Can-Fite BioPharma to Hold Investor Webinar and Q&A Session with CEO on November 25, 2019
Nov 11, 2019 7:00am EST Can-Fite Granted U.S. Patent for Piclidenoson in the Treatment of Osteoarthritis, Positioning this Indication for Animal Health Market
Nov 04, 2019 7:00am EST Can-Fite Initiates Compassionate Use Program for Namodenoson in the Treatment of Liver Cancer, Enrolls and Treats Patients
Oct 31, 2019 7:00am EDT U.S. FDA Agreed with Can-Fite’s Proposed Pivotal Phase III Trial Design to Support a New Drug Application Submission and Approval of Namodenoson in the Treatment of Liver Cancer
Oct 17, 2019 8:00am EDT Can-Fite and Gebro Pharma holding European Conference on Development & Commercialization of Phase III Drug Candidate Piclidenoson in the Treatment of Rheumatoid Arthritis
Oct 16, 2019 7:00am EDT Can-Fite BioPharma Interview to Air on Bloomberg International on the RedChip Money Report
